David A. Siegel Karyopharm Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 76,600 shares of KPTI stock, worth $47,492. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,600

Previous 31,200 145.51%

Holding current value

$47,492

Previous $25,000 108.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.6 - $0.99 $27,240 - $44,946	45,400 Added 145.51%	76,600 $52,000
Q3 2024 Nov 14, 2024	BUY	$0.7 - $1.06 $21,840 - $33,072	31,200 New	31,200 $25,000
Q4 2023 Feb 14, 2024	BUY	$0.68 - $1.31 $19,040 - $36,680	28,000 Added 79.55%	63,200 $54,000
Q3 2023 Nov 14, 2023	SELL	$1.14 - $1.81 $256,499 - $407,250	-225,000 Reduced 86.47%	35,200 $47,000
Q2 2023 Aug 14, 2023	SELL	$1.79 - $4.59 $252,927 - $648,567	-141,300 Reduced 35.19%	260,200 $465,000
Q1 2023 May 15, 2023	SELL	$2.84 - $3.92 $856,828 - $1.18 Million	-301,700 Reduced 42.9%	401,500 $1.56 Million
Q4 2022 Feb 14, 2023	SELL	$2.48 - $5.93 $317,688 - $759,633	-128,100 Reduced 15.41%	703,200 $2.39 Million
Q3 2022 Nov 14, 2022	SELL	$4.08 - $5.82 $631,176 - $900,354	-154,700 Reduced 15.69%	831,300 $4.54 Million
Q2 2022 Aug 15, 2022	BUY	$4.15 - $8.37 $874,405 - $1.76 Million	210,700 Added 27.18%	986,000 $4.45 Million
Q1 2022 May 16, 2022	BUY	$5.91 - $14.38 $2.05 Million - $5 Million	347,700 Added 81.31%	775,300 $5.71 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $8.61 $3.41 Million - $5.63 Million	-654,400 Reduced 60.48%	427,600 $2.75 Million
Q3 2021 Nov 15, 2021	BUY	$4.45 - $10.63 $443,220 - $1.06 Million	99,600 Added 10.14%	1,082,000 $6.3 Million
Q2 2021 Aug 16, 2021	BUY	$8.11 - $11.11 $585,542 - $802,142	72,200 Added 7.93%	982,400 $10.1 Million
Q1 2021 May 17, 2021	BUY	$9.85 - $17.69 $3.97 Million - $7.13 Million	403,300 Added 79.56%	910,200 $9.58 Million
Q4 2020 Feb 16, 2021	SELL	$14.15 - $17.19 $9.61 Million - $11.7 Million	-679,000 Reduced 57.26%	506,900 $7.85 Million
Q3 2020 Nov 16, 2020	BUY	$14.14 - $19.71 $3.99 Million - $5.57 Million	282,400 Added 31.26%	1,185,900 $17.3 Million
Q2 2020 Aug 14, 2020	BUY	$16.6 - $25.25 $2.85 Million - $4.33 Million	171,400 Added 23.41%	903,500 $17.1 Million
Q1 2020 May 15, 2020	BUY	$14.38 - $27.72 $2.99 Million - $5.76 Million	207,900 Added 39.66%	732,100 $14.1 Million
Q4 2019 Feb 14, 2020	BUY	$9.23 - $19.67 $2.96 Million - $6.31 Million	320,700 Added 157.59%	524,200 $10 Million
Q3 2019 Nov 14, 2019	SELL	$5.66 - $11.85 $525,248 - $1.1 Million	-92,800 Reduced 31.32%	203,500 $1.96 Million
Q2 2019 Aug 14, 2019	SELL	$4.32 - $6.43 $320,976 - $477,749	-74,300 Reduced 20.05%	296,300 $1.78 Million
Q1 2019 May 15, 2019	BUY	$4.12 - $10.25 $564,852 - $1.41 Million	137,100 Added 58.72%	370,600 $2.16 Million
Q4 2018 Feb 14, 2019	SELL	$8.2 - $16.95 $40,180 - $83,055	-4,900 Reduced 2.06%	233,500 $2.19 Million
Q3 2018 Nov 14, 2018	BUY	$17.03 - $21.18 $1.39 Million - $1.73 Million	81,900 Added 52.33%	238,400 $4.06 Million
Q2 2018 Aug 14, 2018	BUY	$12.0 - $19.88 $1.88 Million - $3.11 Million	156,500 New	156,500 $2.66 Million

Others Institutions Holding KPTI

# of Institutions

Shares Held

57.1M

Call Options Held

604K

Put Options Held

71.2K

View Full List

About Karyopharm Therapeutics Inc.

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $49.5M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

More about KPTI

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account